SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
130.20    2.40 (1.88%)
Bid:
130.00
Ask:
130.40
Spread: 0.40 (0.308%)
Market Cap: £268.15m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Full Year 2025 Trading Update

22 Jan 2026 07:00

RNS Number : 8534P
Forterra plc
22 January 2026
 

22 January 2026

FORTERRA PLC

 

Full Year 2025 Trading Update

 

Adjusted EBITDA in line with expectations

 

Forterra plc (the 'Group'), a leading UK manufacturer of essential clay and concrete building products, provides its post close trading update for the year ended 31 December 2025 ('FY25') ahead of its full year results announcement scheduled for 11 March 2026.

 

Summary

 

· Revenue of c.£386m, 12% ahead of the prior year (2024: £344.3m)

 

· Adjusted EBITDA in line with market expectations* with margin progression, adjusted PBT and adjusted EPS ahead

 

· Strong progress on debt reduction; net debt before leases of c.£56m (2024: £84.9m) with leverage approximately 1 x adjusted EBITDA

 

Trading and Results

 

FY25 revenue totalled c.£386m, 12% ahead of the comparative (2024: £344.3m), driven primarily by sales volumes. As expected, we saw a moderation of quarterly growth rates through the year due to stronger comparatives and Budget related uncertainty. Whilst demand reduced from the levels seen around the middle of the year, brick remained the most resilient of our product lines.

 

Adjusted EBITDA is expected to be in line with market expectations* with margin progression. Lower interest and depreciation charges benefit adjusted PBT and adjusted EPS, both of which are expected to be ahead of market expectations.

 

UK domestic brick despatches for the 11 months to November 2025, as reported by the Department for Business and Trade, increased by 6% relative to the prior year, with our own despatches outperforming the wider market led by our exposure to housebuilding, with our brick market share continuing to recover towards historic levels.

 

We have continued to make strong progress in reducing the Group's indebtedness, with closing net debt before leases decreasing to c.£56m (2024: £84.9m). Leverage calculated on a banking covenant basis is approximately 1 x adjusted EBITDA. Having returned leverage to targeted levels, we will provide further clarity on our future capital allocation priorities with our full year results. 

Outlook

Given the timing of the November 2025 Budget being so late in the year, alongside the mid-December 2025 cut in interest rates, it is too early to assess the impact of these events on demand.

Longer term market fundamentals remain attractive with a shortage of housing, a strong desire within Government to address this, and a constrained supply of essential building products. The Board remains confident that our recent investments in new production capacity leave the Group well placed to benefit from the market's structural growth drivers and a sustained recovery when it occurs.

 

*Company compiled analyst consensus forecasts are for adjusted EBITDA of £61.6m, adjusted PBT of £32.5m and adjusted EPS of 11.8p.

 

ENQUIRIES

 

 

 

Forterra plc

+44 1604 707 600

Neil Ash, Chief Executive Officer

Ben Guyatt, Chief Financial Officer

FTI Consulting

+44 203 727 1340

Richard Mountain / Nick Hasell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAOBRNWUAUAR
Date   Source Headline
11th Jun 20262:52 pmRNSGrant under Long Term Incentive Plan
11th Jun 20267:00 amRNSDirectorate change
9th Jun 202611:53 amRNSHolding(s) in Company
9th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20269:45 amRNSTransaction in Own Shares
2nd Jun 202612:32 pmRNSEmployee Benefit Trust Share Purchase
2nd Jun 202612:30 pmRNSTotal Voting Rights and Capital
1st Jun 20267:00 amRNSAppointment of New Independent NED
27th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:03 pmRNSHolding(s) in Company
19th May 20264:41 pmRNSAnnual General Meeting 2026 Results
19th May 20267:01 amRNSTransaction in Own Shares
19th May 20267:00 amRNSAGM Trading Update
12th May 20261:32 pmRNSTransaction in Own Shares
12th May 20267:00 amRNSAGM RESOLUTION – APPROVAL OF REMUNERATION POLICY
7th May 20261:43 pmRNSHolding(s) in Company
6th May 202610:50 amRNSTransaction in Own Shares
6th May 20269:58 amRNSTotal Voting Rights and Capital
6th May 20269:55 amRNSEmployee Benefit Trust Share Purchase
28th Apr 202610:20 amRNSHolding(s) in Company
28th Apr 202610:18 amRNSTransaction in Own Shares
21st Apr 202611:31 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSEmployee Benefit Trust Share Purchase
15th Apr 20265:40 pmRNSNotice of Annual General Meeting 2026
14th Apr 202610:00 amRNSTransaction in Own Shares
14th Apr 20267:00 amRNSAppointment of new Independent NED
9th Apr 202610:15 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSDirector Declaration
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20262:07 pmRNSTotal Voting Rights
7th Apr 202612:47 pmRNSEmployee Benefit Trust Share Purchase
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20261:03 pmRNSDirector / PCA Shareholdings
25th Mar 202610:50 amRNSAnnual Report and Accounts 2025
24th Mar 202610:40 amRNSTransaction in Own Shares
24th Mar 20269:01 amRNSHolding(s) in Company
24th Mar 20267:00 amRNSReplacement:Grant under Deferred Annual Bonus Plan
20th Mar 20268:45 amRNSGrant under Deferred Annual Bonus Plan
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 20263:27 pmRNSEmployee Benefit Trust Share Purchase
18th Feb 20262:27 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202612:26 pmRNSEmployee Benefit Trust Share Purchase
29th Jan 20268:33 amRNSHolding(s) in Company
28th Jan 20269:21 amRNSHolding(s) in Company
26th Jan 20264:07 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSFull Year 2025 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.